Joel YR

oncólogo médico

[Dr Rishabh Jain @DrRishabhOnco]

🚨 NEW CSCO–ASCO Guidelines for Recurrent/Metastatic Nasopharyngeal Cancer!

Key takeaways from JCO (2026):

🔹 1L: Gemcitabine/cisplatin + PD-1 inhibitor → PD-1 maintenance up to 2 years

🔹 Chemo-only responders: Capecitabine/S-1 maintenance

🔹 Selected de novo metastatic NPC: Consolidation IMRT

🔹 After ≥2 lines including platinum + PD-1: Izalontamab brengitecan ADC, where available

💡 Important: PD-L1 testing is NOT required before first-line PD-1 therapy. Evidence is insufficient to add oral chemotherapy to PD-1 maintenance.

A practical roadmap for a rapidly evolving disease!

@oncoalert

Full paper link in comment below ⬇️

[Yakup Ergün @dr_yakupergun]

Historical timeline of kinase drug discovery👇

https://t.co/OcZRzFk0mz

(The expansion of kinase drug discovery: new targets, platforms and indications)

[Yakup Ergün @dr_yakupergun]

Cancer drug resistance as a temporal process: cell plasticity, adaptive buffering, signaling pathways and therapeutic interception

https://t.co/6mn4UKkjGm

[Yakup Ergün @dr_yakupergun]

Evolving First-Line Treatment Strategies in ERBB2-Positive Metastatic Breast Cancer
https://t.co/v1ioHv7g2m

[Ｊｕｎ Ｙａｓｕｄａ @jyasuda1]

膵臓癌の4割程度がセリン合成系に障害があり、神経細胞からセリン供給を受けることは知られていたようだが、神経支配のない転移巣ではどうなのかが不明だった。肝細胞ではCXCL5-CXCR2系の活性によって転移膵癌細胞にセリンを供給することを明らかにした論文。Nature。
https://t.co/TGHTinn3Pi

[Erman Akkus @Erman_Akkus]

Analytical and clinical comparison of three PD-L1 antibody clones using Tumor Area Positivity (TAP) and Combined Positive Score (CPS) scoring in advanced gastric cancer

https://t.co/vJAuL4EVkv

[Yukinori Ozaki, MD, Ph.D @YukinoriOzaki]

🇪🇸Overview of ESMO2026 Breast Cancer topics!!🌏 #ESMO26
@Ganken_hosp
@GustaveRoussy
@OncoAlert
@JCOG_official
#BreastCancer #ESMO

[Dr Rishabh Jain @DrRishabhOnco]

🚨 ASCO 2026: PARP inhibitors in ovarian cancer. What has changed?

The new ASCO Living Guideline, published in @JCO_ASCO, reviewed 31 pivotal trials and 13 HRD assays.

1️⃣ First-line maintenance: The preferred window for PARPi

🔹 SOLO-1: Olaparib established durable benefit in BRCA-mutated disease.

🔹 PRIMA / PRIME: Niraparib improved PFS, with the greatest benefit in HRD-positive disease.

🔹 ATHENA-MONO: Rucaparib demonstrated PFS benefit, particularly in HRD-positive tumors.

🔹 PAOLA-1: Olaparib + bevacizumab benefits patients with HRD-positive disease following platinum + bevacizumab.

2️⃣ Biomarker selection is critical

✅ BRCA-mutated or HRD-positive: Offer first-line PARPi maintenance after platinum response.

❌ BRCA-wild-type / HRD-negative: Not routinely recommended, despite modest PFS signals in PRIMA and ATHENA-MONO.

3️⃣ Recurrent ovarian cancer: A major restriction

🔹 SOLO-2 / NOVA / ARIEL3: PFS benefits established, but mature OS findings raised concerns in some subgroups.

➡️ Recurrent maintenance is now primarily reserved for PARPi-naïve, BRCA-mutated patients responding to platinum.

4️⃣ PARPi as treatment, not maintenance?

🔹 SOLO-3 / ARIEL4: Concerning OS findings altered the risk-benefit assessment.

❌ PARPi monotherapy is NOT recommended for treatment of recurrent ovarian cancer outside clinical trials.

5️⃣ What about PARPi rechallenge?

🔹 OReO / ENGOT-ov38: Modest PFS benefit, but insufficient evidence for routine PARPi rechallenge.

The clinical takeaway:

PARPi treatment is moving from broad use across multiple lines toward earlier, biomarker-selected maintenance.

The question is no longer simply “Is the patient platinum-sensitive?”

It is “BRCA? HRD? Prior PARPi exposure? Which line of therapy?”

@ASCO @myesmo @ESMO_open

#OvarianCancer #PARPi #ESMO26

Full paper link in comment below ⬇️

[Yakup Ergün @dr_yakupergun]

#ESMO26

HR+/HER2− MBC: Proposed 2L / 3L treatment algorithm

[LARVOL @Larvol]

postMONARCH trial: Updated data from @myESMO 2026 in 2L+ HR+/HER2- BC: ET + CDK4/6 Inhibitiors landscape, adapted from Dr. Allan Ramos-Esquivel, Dr. Isaac Ramírez-Jiménez, Dr. Alvaro Víquez-Jaikel 👉 https://t.co/Na7ErMMi9h

Updated landscape 👉 https://t.co/7gWd2LqXgD

Explore #ESMO26 insights here: https://t.co/JBaV2QEuxu

#LARVOL #ESMO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #MedicalOncology #ClinicalTrials #BreastCancer #BCSM | @PTarantinoMD | @hoperugo | @ErikaHamilton9 | @stolaney1 | @drsarahsam | @DrHBurstein

[Eric Topol @EricTopol]

What is "medical superintelligence" and why are we so far away from the concept?
open-access
https://t.co/yZrHHPR4t1

[Yakup Ergün @dr_yakupergun]

#ESMO26

Progress in Classical EGFR-Mutated NSCLC

From Dr. Natasha Leighl's discussion

[Anirban Maitra @Aiims1742]

Striking a Nerve in #PancreaticCancer: Unraveling the Crosstalk Between Tumor Cells and Neurons
https://t.co/4toraagGv1

[Yakup Ergün @dr_yakupergun]

#ESMO26

Current Guidelines for Stage I Triple-Negative Breast Cancer
From @lab_kok excellent presentation👇

[Nieves Martinez Lago MD PhD @DraMartinezLago]

#ESMO26 💊 LOMAC | Phase III | Rapid Oral

👥 1,023 pts | Stage II–III gastric cancer after D2 surgery

🔀 XELOX 4 vs 6 months

✅ 3-y DFS: 69.2% vs 70.8% (HR 1.01) → Noninferior

⚠️ G≥3 AEs: 8.4% vs 15%
📈 Completion: 83.6% vs 60.4%

💡 Shorter treatment, less toxicity!

@OncoAlert

[Yakup Ergün @dr_yakupergun]

Three HER2-targeting ADCs in HER2-low breast cancer.

Same target, same linker, same payload class (TOP1 inhibitors).

Three ADCs superior to chemotherapy. Three me-too ADCs???

[Yakup Ergün @dr_yakupergun]

#ESMO26

Optimal duration of adjuvant endocrine therapy: 5, 7–8, or 10 years?

From Dr. Fumikata Hara’s excellent discussion👇

[Rohit Malde @roxboxfix]

Treatment of Advanced Biliary Tract Cancer: ASCO Living Guideline, Version 2026.1.0

DOI: 10.1200/JCO-26-02462⁠

Summary of All Recommendations:

Biomarker Testing

First-line therapy for patients with
pMMR/MSS & dMMR/MSI-H Advanced
BTC

2nd Line Rx with/without Targeted Rx

[Dr Rishabh Jain @DrRishabhOnco]

🚨 NEW ASCO 2026 GUIDELINE: Recurrent Ovarian Cancer

A practical treatment algorithm worth saving 👇

PLATINUM-SENSITIVE recurrence
→ Platinum doublet remains backbone:
• Carboplatin + PLD
• Carboplatin + paclitaxel
• Carboplatin + gemcitabine
→ Bevacizumab may be added, followed by maintenance bevacizumab
→ Do NOT add trabectedin to PLD

PLATINUM-RESISTANT / REFRACTORY
⭐ FRα-high: Mirvetuximab soravtansine = strong recommendation
Other options:
• PLD
• Paclitaxel
• Bevacizumab + chemotherapy
• Relacorilant + nab-paclitaxel
• Gemcitabine

SURGERY
Secondary cytoreduction is not routinely recommended based on current evidence, but may be discussed when complete gross resection is highly achievable.

HIPEC
Evidence remains insufficient for a routine recommendation.

Key message:
Recurrent ovarian cancer is becoming increasingly biomarker-driven and patient-selected, especially in platinum-resistant disease.

@ASCO @JCO_ASCO @OncoAlert
#OvarianCancer #GynOnc #Oncology

[Yakup Ergün @dr_yakupergun]

The top cancer success stories of the past 50 years, by the numbers
https://t.co/MF5wnaP3ax